Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells

[1] Jawad N(2019)The clinical and radiologic features of paediatric rhabdomyosarcoma Pediatr Radiol 49 1516-1523

[2] McHugh K(2010)Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma J Clin Oncol 28 2151-2158

[3] Williamson D(2012)PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification J Clin Oncol 30 1670-1677

[4] Missiaglia E(2013)PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report Pediatr Blood Cancer 60 1411-1417

[5] Reyniès AD(2003)Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the intergroup rhabdomyosarcoma study IV J Clin Oncol 21 78-84

[6] Pierron G(2014)Rhabdomyosarcoma in adolescent and young adult patients: current perspectives Adolesc Health Med Therap 5 115-125

[7] Thuille B(2014)Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS BMC Cancer 14 139-375

[8] Palenzuela G(2016)High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas Cancer Cell Int 16 59-2638

[9] Thway K(2012)EZH2: a pivotal regulator in controlling cell differentiation Am J Transl Res 4 364-3836

[10] Orbach D(2004)The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation Genes Dev 18 2627-2365

[1] Jawad N(2019)The clinical and radiologic features of paediatric rhabdomyosarcoma Pediatr Radiol 49 1516-1523

[2] McHugh K(2010)Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma J Clin Oncol 28 2151-2158

[3] Williamson D(2012)PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification J Clin Oncol 30 1670-1677

[4] Missiaglia E(2013)PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report Pediatr Blood Cancer 60 1411-1417

[5] Reyniès AD(2003)Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the intergroup rhabdomyosarcoma study IV J Clin Oncol 21 78-84

[6] Pierron G(2014)Rhabdomyosarcoma in adolescent and young adult patients: current perspectives Adolesc Health Med Therap 5 115-125

[7] Thuille B(2014)Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS BMC Cancer 14 139-375

[8] Palenzuela G(2016)High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas Cancer Cell Int 16 59-2638

[9] Thway K(2012)EZH2: a pivotal regulator in controlling cell differentiation Am J Transl Res 4 364-3836

[10] Orbach D(2004)The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation Genes Dev 18 2627-2365